Kate Gifford 
Atropine 0.01% combined with orthokeratology slows axial elongation to less than 0.1mm/year over two years in Chinese children aged 6-11 years. This is the equal-longest study on this topic and first to measure potential mechanisms of pupil size and choroidal thickness. The largest effect of the combination occurred in the first 6 months.
The International Myopia Institute released their Volume 1 of reports in 2019 and Volume 2 in 2021. Here, we explore the latest round of reports in 2021 and what they each mean for clinical practice.
If your patient is a unilateral myope, sometimes the myopic eye is the easier one to manage! This case study explores the options to appropriately diagnose, track and manage the non-myopic eye in a unilateral myope – where the non-myopic eye seems to be progressing faster than the myopic eye treated with orthokeratology.
What does on-label and off-label prescribing mean in myopia management? Here we explore this topic from the point of view of medications and medical devices, what regulatory approvals mean and how this applies to decision making and clinical processes such as informed consent.
This new systematic review and meta-analysis has evaluated use of smartphones and tablets separately to computer use and other non-screen based near work. Results are still mixed but overall there was a trend for a slightly increased risk with mobile device use alone, which increased when combined with computer use. More objective measures of screen time are needed to further explore this link.
This study reports two year results from a randomized clinical trial examining myopia control spectacle lenses with highly aspherical lenslets (HAL) or slightly aspherical lenslets (SAL). The findings showed the HAL lens controlled refractive and axial progression by 50-55% and SAL by around 30% over two years. Read more about the outcomes and comparisons to other myopia control spectacles here.
This study showed that aspheric multifocal soft contact lenses (Biofinity +2.50D and NaturalVue) reduce accommodative response and increase exophoria, while MiSight concentric dual-focus minimally impacts binocular vision function compared to single vision contact lenses. All myopia control contact lenses increased divergence range slightly but did not impact convergence.
The MiSight 1 day clinical trial is the longest in soft lens myopia control, showing efficacy in children and teens in up to 6 years of wear. The first three years showed a 50-60% axial length and refractive efficacy. In the second three years, all control group children were switched to MiSight and showed axial growth similar to children under continued treatment, indicating benefits for commencing wear in children and teens alike.
The Low-Concentration Atropine for Myopia Progression (LAMP) Study has provided invaluable data on comparisons between 0.05%, 0.025% and 0.01% atropine treatment. The three year data has shown 0.05% to be most effective for continued treatment, while children discontinued showed a small, ‘clinically insignificant’ rebound effect. Learn more about the one, two and three year LAMP data here.
In 2021, the World Council of Optometry (WCO) passed a resolution that publicly declares support for myopia management as standard of care. Since then, CooperVision has supported the WCO to empower eye care professionals to put this into action, with a multilingual online resource launched and more being added throughout 2022. Explore and learn more here.
